去纤苷适合什么人用？

It is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. Who is defibrinoside suitable for?

Indications of defibrotide: It is suitable for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Use of defibrinoside in special groups:

Defibrinated sodium medication for pregnant women: Please consult your doctor for details.

Defibrotide Sodium Pediatric Medication: The safety and effectiveness of the medication in minor patients have not been determined.

Defibrotide use in the elderly: Clinical studies of defibrotide did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently than younger subjects. Other reported clinical experience has not identified differences in response between older and younger patients.

In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT; October 2013. Defibrotide is approved for marketing in the EU.

On March 30, 2016, defitelioside was approved by the U.S. Food and Drug Administration (FDA) to be launched in the United States under the trade name Defitelio.

Therapeutic effects of defibrotide:

In clinical trials, heparin was used to prevent diseases such as hepatic veno-occlusion while greatly increasing the risk of bleeding, while defibrinoside alone or in combination with heparin had a very low incidence of side effects and achieved good results in preventing HVOD.

In a phase III multi-center randomized clinical trial completed in Europe, a total of 356 stem cell transplant patients were recruited. The incidence of hepatic vein occlusion 30 days after transplantation was compared. It was found that 2 of 180 patients in the group developed hepatic vein occlusion, accounting for 12%; and 35 of 176 patients in the control group developed hepatic vein occlusion, accounting for 20%.

Recommended related hot articles: /newsDetail/74969.html